Because of their safety and the fact that they are not perceived as “medicine,” food-derived
products are highly interesting for development as chemopreventive agents that may find …

Mounting evidence suggests that lipoxygenase (LO)-catalyzed products have a profound
influence on the development and progression of human cancers. Compared with normal …

Colorectal cancer is the second leading cause of mortality in the United States. In the United
States, the cumulative lifetime risk of developing colorectal cancer for both men and women …

Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is a
common autosomal dominant syndrome characterized by early age at onset, neoplastic …

Background Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the
number of colorectal adenomas in animals and patients with familial adenomatous …

Abstract The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of
the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention …

This article reviews progress in chemopreventive drug development, especially data and
concepts that are new since the 2002 AACR report on treatment and prevention of …

Clinical chemoprevention trials of more than 30 agents and agent combinations are now in
progress or being planned. The most advanced agents are well known and are in large …

This is the second publication of Clinical Development Plans from the National Cancer
Institute, Division of Cancer Prevention and Control, Chemoprevention Branch and Agent …

Hereditary non-polyposis colorectal cancer is almost always associated with microsatellite
instability, so what is the best way to identify the disorder at an early-stage, and what should …